摘要
非酒精性脂肪性肝病在全球发病率持续上升,由于其复杂的发病机制,尚未开发出有效的治疗药物。该病若未得到及时治疗,可能加剧糖尿、高血脂等相关代谢性疾病发生的风险,严重会导致肝纤维化,甚至发生肝硬化。胰高血糖素样肽-1是小肠L型细胞分泌的一种激素,具有调节葡萄糖依赖性的胰岛素分泌刺激,减少胃排空,抑制食物摄取等作用。综述了胰高血糖素样肽-1受体激动剂对非酒精性脂肪性肝病的治疗作用及其相关机制。
The incidence rate of nonalcoholic fatty liver disease(NAFLD)continues to rise around the world,and due to its complex pathogenesis,there is still a lack of effective treatment drugs.If NAFLD is not treated in time,it may increase the risk of related metabolic diseases such as diabetes and hyperlipidemia and even lead to liver fibrosis and liver cirrhosis.Glucagon-like peptide-1 is a hormone secreted by L-shaped cells of the small intestine and can regulate glucose-dependent stimulation of insulin secretion,reduce gastric emptying,and inhibit food intake.This article reviews the effect of glucagon-like peptide-1 receptor agonist in the treatment of NAFLD and related mechanism.
作者
俞晓菡
王雨露
许笑阳
平键
赵长青
YU Xiaohan;WANG Yulu;XU Xiaoyang;PING Jian;ZHAO Changqing(Institute of Hepatology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Second Department of Hepatology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Shanghai Key Laboratory of Traditional Chinese Clinical Medicine,Shanghai 201203,China;Key Laboratory of Liver and Kidney Diseases,Ministry of Education,Shanghai 201203,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2021年第1期196-199,共4页
Journal of Clinical Hepatology
基金
国家自然科学基金(81673780)。
关键词
非酒精性脂肪性肝病
胰高血糖素样肽-1受体
药理作用分子作用机制
Non-alcoholic Fatty Liver Disease
Glucagon-Like Peptide-1 Receptor
Molecular Mechanisms of Pharmacological Action
作者简介
俞晓菡(1996-),女,主要从事中西医结合抗肝纤维化方面的研究;通信作者:赵长青,cathy090909@126.com。
